<DOC>
	<DOCNO>NCT01755078</DOCNO>
	<brief_summary>The study design compare sevelamer vs. calcium-based phosphate binder hemodialysis patient achieve full-scale medical care , include reduction atherosclerotic risk factor , reduction vascular access reconstruction rate , pharmacoeconomic analysis .</brief_summary>
	<brief_title>Long Term Evaluation Sevelamer HCl vs. Calcium-based Phosphate Binder Treatment Hyperphosphatemia Hemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<mesh_term>Calcium acetate</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Males female age 1870 year old Subject hyperphosphatemia ( 5.5 8.5 mg/dL ) WK ( 2 ) WK0 On stable TIW hemodialysis 3 month long Patients hypercalcemia ( correct serum calcium &gt; 10.5 mg/dL ) Any follow abnormality : ALT AST &gt; 3X ULN ; iPTH &gt; 1000 &lt; 150 pg/mL History dysphagia swallow disorder History GI motility disorder GI bleeding within 3 month prior entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Phosphate binder</keyword>
</DOC>